ClostraBio

ClostraBio is focused on restoring intestinal barrier-protective function and innate immunity to maintain gut health and treat diseases of the gut and food allergy. The company leverages a well-rounded team of scientists and entrepreneurs with expertise in microbiology and bioengineering to develop both a dietary supplement and a versatile delivery platform. Their core technology aims to transform intestinal health through targeted metabolite delivery, addressing significant unmet needs in the IBD and food allergy markets.

A plug-and-play platform for the targeted delivery of bacterial metabolites to the gut, designed to restore intestinal barrier function and modulate innate immunity for treating gastrointestinal and allergic diseases.

ClostraBio faces competition from large pharma in IBD (AbbVie, J&J) and food allergy (Nestlé/Aimmune), as well as other microbiome biotechs (Vedanta, Seres). Its differentiation is the focus on targeted delivery of specific metabolites, rather than live bacteria, aiming for precise modulation of gut physiology.